Phoebus Medical Technology

Established in December 2015 in Shanghai, China, Phoebus Medical Technology is a privately held company operating in the health-tech sector, specializing in artificial intelligence-driven solutions for chronic disease management. The company, also known as Shanghai Fushi Medical Technology Co., Ltd., was co-founded by CEO Wang Yun and has secured venture capital, including a Series A funding round in November 2018 that raised several tens of millions of RMB from investors like Cenova Capital and Shanghai Alliance Investment.

Phoebus Medical focuses on providing a comprehensive chronic disease management platform centered on patients, with a primary entry point of monitoring diabetic retinopathy. The business serves grassroots medical institutions by offering integrated solutions that assist with tiered diagnosis and treatment, aiming to reduce medical expenses. Its business model involves a B2B approach, selling directly to healthcare providers, and also a B2B2C model, where their services are ultimately delivered to patients through these institutions. The company generates revenue through various means, including partnerships to offer diversified services that cover the entire patient journey from screening and monitoring to consultation and medication.

The core of Phoebus Medical's offering is an AI-powered screening system paired with a portable handheld fundus camera, designed for the accessibility needs of primary care facilities. Recognizing the shortage of ophthalmologists, the company developed a remote screening platform where ophthalmologists from major hospitals provide diagnostic readings within eight hours, facilitating timely patient assessment and referral. This platform is part of a broader service that includes screening, monitoring, education, and follow-up, helping patients with conditions like diabetes and hypertension mitigate the risk of complications. Phoebus Medical has established a significant footprint, collaborating with nearly 800 medical institutions across 20 provinces and 125 cities in China, and has served over 500,000 diabetic patients by creating traceable chronic disease profiles.

Keywords: chronic disease management, AI medical screening, diabetic retinopathy, health-tech, medical technology, Shanghai, remote diagnostics, fundus camera, primary healthcare solutions, venture capital-backed, B2B healthcare, patient monitoring, preventative medicine, medical data platform, healthcare solutions provider, digital health, telemedicine, AI-assisted diagnostics, ophthalmology technology, tiered healthcare